

Accepted Manuscript

Improved outcomes with proactive versus reactive therapeutic drug monitoring of infliximab in IBD

Konstantinos Papamichael, Mark T. Osterman, Adam S. Cheifetz



PII: S1542-3565(17)30693-6
DOI: [10.1016/j.cgh.2017.06.004](https://doi.org/10.1016/j.cgh.2017.06.004)
Reference: YJCGH 55285

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 5 June 2017

Please cite this article as: Papamichael K, Osterman MT, Cheifetz AS, Improved outcomes with proactive versus reactive therapeutic drug monitoring of infliximab in IBD, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2017.06.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Improved outcomes with proactive versus reactive therapeutic drug monitoring of**
2 **infliximab in IBD**

3 Konstantinos Papamichael¹, Mark T. Osterman², and Adam S. Cheifetz¹

4 ¹Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess
5 Medical Center, Harvard Medical School, Boston, Massachusetts.

6 ²Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
7 Philadelphia, Pennsylvania.

8

9 **Corresponding author:**

10 Adam S. Cheifetz, MD

11

12 Director, Center for Inflammatory Bowel Disease
13 Beth Israel Deaconess Medical Center
14 330 Brookline Ave., Rabb 425, Boston, MA 02215
15 Associate Professor of Medicine, Harvard Medical School
16 e-mail: acheifet@bidmc.harvard.edu
17 Phone: (617) 667-2802, Fax: (617) 667-5826

18

19 **Short title:** Therapeutic drug monitoring in IBD

20

21 **ABBREVIATIONS:** IBD: inflammatory bowel disease; TDM: therapeutic drug monitoring;
22 CRP: C-reactive protein.

23

24 **WRITING ASSISTANCE:** None.

25

26 **AUTHOR CONTRIBUTIONS:** K.P., M.T.O., and A.S.C. drafted the manuscript. All the
27 authors reviewed and approved the final manuscript.

Download English Version:

<https://daneshyari.com/en/article/5657307>

Download Persian Version:

<https://daneshyari.com/article/5657307>

[Daneshyari.com](https://daneshyari.com)